24/7 Market News Snapshot 09 April, 2025 – Phio Pharmaceuticals Corp. Common Stock (NASDAQ:PHIO)

April 9, 2025

DENVER, Colo., 09 April, 2025 (www.247marketnews.com) – (NASDAQ:PHIO) are discussed in this article.
Phio Pharmaceuticals Corp. has demonstrated a significant bullish trend, with shares rising to $1.298, marking an impressive 28.51% increase in pre-market trading. This surge, supported by a trading volume of 2.70 million shares, reflects heightened investor confidence. Enthusiasm in the biotech sector appears to be bolstered by promising developments, particularly in immuno-oncology therapies.

In a notable development, the Safety Monitoring Committee (SMC) has recommended advancing the Phase 1b clinical trial of PH-762, Phio’s lead product candidate designed for treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The trial’s initial cohorts have yielded encouraging data, paving the way for dose escalation based on the treatment’s safety and tolerability. The third cohort treatment outcome is particularly noteworthy, with three patients showing well-tolerated responses and no serious adverse events. Earlier cohorts reported compelling results, including complete responses in two patients and significant tumor reduction in another.

Dr. Mary Spellman, acting Chief Medical Officer, conveyed optimism about the treatment’s safety profile as the trial progresses, while Robert Bitterman, President and CEO, emphasized the potential of PH-762 as a non-surgical alternative for challenging skin cancers. Phio’s commitment to leveraging its proprietary INTASYL® siRNA gene silencing technology positions the company to radically transform therapeutic approaches to cancer treatment.

As the clinical trial moves forward, updates on efficacy and outcomes are expected in the coming months, maintaining Phio Pharmaceuticals’ momentum within the biotech landscape. The ongoing advancements underline significant opportunities for investors looking to engage with innovative cancer therapies in a rapidly evolving market.

Related news for (PHIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.